Functional Concept – Page 11

iTeos to Shut Down Operations After TIGIT Therapy Setback

5 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges

5 months ago talkbio0Tagged Antibiotics, Clinical Trials, Complicated, HBr, PIVOT-PO trial, SmithKline Beecham, Spero Therapeutics, Stock Surge, Submission, United States Food and Drug Administration, Urinary tract infection

GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission

Sernova Chair Resigns After Insider Trading Indictment Tied to Novartis-Chinook Deal

5 months ago talkbio0Tagged biotherapeutics, DOJ, indictment, insider trading, News [Publication Type], Novartis-Chinook acquisition, resignation, Ross Haghighat, securities fraud, Sernova

Sernova Biotherapeutics; insider trading; resignation; Ross Haghighat; Novartis-Chinook acquisition; securities fraud; biotech news; DOJ indictment

Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold

5 months ago talkbio0Tagged acute systemic infection, Adverse event, Capillary Leak Syndrome, gene therapy, Glycogen Storage Disease Type IIb, Patient Death, Rocket, RP-A501, Study on Hold, United States Food and Drug Administration

Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge

5 months ago talkbio0Tagged Cancer of Neck, Clinical Trials, Head, Keytruda, Merus, Overall Survival, pembrolizumab, Petosemtamab, Phase 2, Reaction, scenario

Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario

Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.

5 months ago talkbio0Tagged Beak, Budgets, CBO, healthcare changes, Medicare, reconciliation, Sequestration, Transplant Registry Unified Management Program

Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report

FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation

6 months ago talkbio0Tagged Advisory Committees, Availability of, COVID19 (disease), formula update, JN.1-lineage, KP.2 strain, United States Food and Drug Administration, Vaccines

FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026

Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials

6 months ago talkbio0Tagged Accelerated, Approved, CellCentric, Clinical Trials, Inobrodib, Multiple Myeloma, oral drug, p300/CBP inhibitor, Pfizer, Series C

CellCentric; Pfizer; multiple myeloma; Series C funding; inobrodib; p300/CBP inhibitor; oral drug; clinical trials; phase 2/3; accelerated approval

Applied Therapeutics’ Rare Disease Drug Fails Another Phase 3 Trial After FDA Rejection

6 months ago talkbio0Tagged Aldose Reductase Inhibitor, Apply, Cautionary Warning, Classical galactosemia, clinical trial conduct, Govorestat, Infrequent, Rejection, United States Food and Drug Administration

Applied Therapeutics; govorestat; rare disease; phase 3 failure; FDA rejection; classic galactosemia; aldose reductase inhibitor; clinical trial conduct; FDA warning letter

ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty

6 months ago talkbio0Tagged ASCO25, Cancer Research, Changing, Diagnostics, expert, Immunotherapy, Neoplasms, perspectives, Policy, Precision Medicine, regulatory uncertainty

ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes